- Home
- USFD vs GMAB Comparison
USFD vs GMAB Comparison
Compare USFD & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USFD
- GMAB
- Stock Information
- Founded
- USFD 2007
- GMAB 1999
- Country
- USFD United States
- GMAB Denmark
- Employees
- USFD N/A
- GMAB N/A
- Industry
- USFD Food Distributors
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- USFD Consumer Discretionary
- GMAB Health Care
- Exchange
- USFD Nasdaq
- GMAB Nasdaq
- Market Cap
- USFD 15.6B
- GMAB 15.0B
- IPO Year
- USFD 2016
- GMAB N/A
- Fundamental
- Price
- USFD $64.67
- GMAB $20.59
- Analyst Decision
- USFD Strong Buy
- GMAB Buy
- Analyst Count
- USFD 12
- GMAB 8
- Target Price
- USFD $70.08
- GMAB $43.00
- AVG Volume (30 Days)
- USFD 1.8M
- GMAB 1.5M
- Earning Date
- USFD 11-07-2024
- GMAB 11-06-2024
- Dividend Yield
- USFD N/A
- GMAB N/A
- EPS Growth
- USFD 29.12
- GMAB 14.35
- EPS
- USFD 2.34
- GMAB 10.80
- Revenue
- USFD $37,322,000,000.00
- GMAB $2,967,926,227.00
- Revenue This Year
- USFD $8.48
- GMAB $30.31
- Revenue Next Year
- USFD $5.26
- GMAB $16.49
- P/E Ratio
- USFD $27.69
- GMAB $18.52
- Revenue Growth
- USFD 6.10
- GMAB 17.75
- 52 Week Low
- USFD $42.19
- GMAB $20.50
- 52 Week High
- USFD $68.00
- GMAB $32.89
- Technical
- Relative Strength Index (RSI)
- USFD 56.34
- GMAB 25.31
- Support Level
- USFD $61.28
- GMAB $21.90
- Resistance Level
- USFD $68.00
- GMAB $23.47
- Average True Range (ATR)
- USFD 1.37
- GMAB 0.45
- MACD
- USFD 0.18
- GMAB -0.12
- Stochastic Oscillator
- USFD 60.12
- GMAB 3.03
About USFD US Foods Holding Corp.
US Foods Holding Corp is the U.S. food service distributor. us Foods distributes food and nonfood products to the healthcare and hospitality industries, restaurants, and education, government facilities, and grocers. In addition to its delivery business, the firm has 80 cash-and- carry stores under the Chef'Store banner. The company generates majority of the revenue from Meats and seafood products.
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.